サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1390475

ナチュラルキラー細胞療法市場：世界の産業動向、シェア、規模、成長、機会、2023-2028年予測

Natural Killer Cells Therapeutics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028
出版日: | 発行: IMARC | ページ情報: 英文 138 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
ナチュラルキラー細胞療法市場：世界の産業動向、シェア、規模、成長、機会、2023-2028年予測
出版日: 2023年11月24日
発行: IMARC
ページ情報: 英文 138 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

概要

世界のナチュラルキラー細胞療法の市場規模は2022年に25億米ドルに達しました。今後、IMARC Groupは、市場が2028年までに54億米ドルに達し、2022年から2028年の間に13.70%の成長率（CAGR）を示すと予測しています。

ナチュラルキラー（NK）細胞療法は、効率的な細胞傷害性で複数の病原性抗原を標的とし、サイトカインストームのリスクを低減します。NK細胞は、患者特異的な免疫細胞に頼ることなく、さまざまな供給源から産生することができます。現在、サイトカインや低分子薬剤を用いたex vivoプレコンディショニングやキメラ抗原受容体（CAR）NKの作製など、NK細胞療法の有効性を向上させるいくつかの戦略が開発されています。さらに研究者たちは、強力な免疫細胞の強固な増殖、ターゲティングの強化、持続性の延長を通じて、同種NK細胞の治療効果を最大化することに注力しています。これによって、強力かつ持続的な抗がん免疫介在攻撃が可能となります。

ナチュラルキラー細胞療法の市場動向：

がん、感染症、肝障害を患う患者数の大幅な増加は、市場成長を促進する主な要因の一つです。これは、不健康な食事パターン、運動不足、大気汚染の深刻化、アルコールやタバコ製品を摂取する人の増加に起因しています。さらに、がんの発症リスクは加齢とともに劇的に上昇するため、世界中で老年人口が増加していることも、NK細胞療法の需要を促進するもう一つの成長要因となっています。これとは別に、がん患者の免疫応答は十分ではないため、医療企業は同種既製のNK細胞ベースの治療法を通じて免疫応答を高める新しい方法と技術を開発しています。さらに、リスクや毒性を最小限に抑えながらNK細胞ベースの治療効果を高めるため、腫瘍を標的とした抗体戦略に焦点を当てた臨床研究の数も増加しています。さらに、多くの国の行政機関ががん患者に対する資金援助制度を設けており、これが市場に有利な見通しを生み出しています。

本レポートで扱う主な質問

  • 2022年の世界のナチュラルキラー細胞療法市場規模は？
  • 2023-2028年の世界のナチュラルキラー細胞療法市場の予想成長率は？
  • 世界のナチュラルキラー細胞療法市場を牽引する主要因は何か？
  • COVID-19が世界のナチュラルキラー細胞療法市場に与えた影響は？
  • 療法別の世界のナチュラルキラー細胞療法市場の内訳は？
  • 用途別の世界のナチュラルキラー細胞療法市場の内訳は？
  • エンドユーザー別の世界のナチュラルキラー細胞療法市場の内訳は？
  • 世界のナチュラルキラー細胞療法市場における主要地域は？
  • 世界のナチュラルキラー細胞療法市場における主要プレイヤー/企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査目的
  • 利害関係者
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要産業動向

第5章 世界のナチュラルキラー細胞療法市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：療法別

  • NK細胞療法
    • 市場動向
    • 市場予測
  • NK細胞誘導抗体
    • 市場動向
    • 市場予測

第7章 市場内訳：用途別

  • がん
    • 市場動向
    • 市場予測
  • 消化器疾患
    • 市場動向
    • 市場予測
  • 免疫増殖性疾患
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第8章 市場内訳：エンドユーザー別

  • 病院
    • 市場動向
    • 市場予測
  • 研究センター・機関
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第9章 市場内訳：地域別

  • 北米
    • 米国
      • 市場動向
      • 市場予測
    • カナダ
      • 市場動向
      • 市場予測
  • アジア太平洋
    • 中国
      • 市場動向
      • 市場予測
    • 日本
      • 市場動向
      • 市場予測
    • インド
      • 市場動向
      • 市場予測
    • 韓国
      • 市場動向
      • 市場予測
    • オーストラリア
      • 市場動向
      • 市場予測
    • インドネシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • 欧州
    • ドイツ
      • 市場動向
      • 市場予測
    • フランス
      • 市場動向
      • 市場予測
    • 英国
      • 市場動向
      • 市場予測
    • イタリア
      • 市場動向
      • 市場予測
    • スペイン
      • 市場動向
      • 市場予測
    • ロシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • ラテンアメリカ
    • ブラジル
      • 市場動向
      • 市場予測
    • メキシコ
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • 中東・アフリカ地域
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第10章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第13章 価格分析

第14章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Affimed GmbH
    • Bristol-Myers Squibb Company
    • Fate Therapeutics
    • Fortress Biotech Inc.
    • Glycostem Therapeutics
    • Innate Pharma S.A.
    • Kuur Therapeutics Inc.（Athenex Inc.）
    • Nkarta Inc.
    • Takeda Pharmaceutical Company Limited
    • Ziopharm Oncology Inc.
図表

List of Figures

  • Figure 1: Global: Natural Killer Cells Therapeutics Market: Major Drivers and Challenges
  • Figure 2: Global: Natural Killer Cells Therapeutics Market: Sales Value (in Billion US$), 2017-2022
  • Figure 3: Global: Natural Killer Cells Therapeutics Market Forecast: Sales Value (in Billion US$), 2023-2028
  • Figure 4: Global: Natural Killer Cells Therapeutics Market: Breakup by Therapeutics (in %), 2022
  • Figure 5: Global: Natural Killer Cells Therapeutics Market: Breakup by Application (in %), 2022
  • Figure 6: Global: Natural Killer Cells Therapeutics Market: Breakup by End User (in %), 2022
  • Figure 7: Global: Natural Killer Cells Therapeutics Market: Breakup by Region (in %), 2022
  • Figure 8: Global: Natural Killer Cells Therapeutics (NK Cell Therapies) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 9: Global: Natural Killer Cells Therapeutics (NK Cell Therapies) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 10: Global: Natural Killer Cells Therapeutics (NK Cell Directed Antibodies) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 11: Global: Natural Killer Cells Therapeutics (NK Cell Directed Antibodies) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 12: Global: Natural Killer Cells Therapeutics (Cancer) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 13: Global: Natural Killer Cells Therapeutics (Cancer) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 14: Global: Natural Killer Cells Therapeutics (Gastrointestinal Diseases) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 15: Global: Natural Killer Cells Therapeutics (Gastrointestinal Diseases) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 16: Global: Natural Killer Cells Therapeutics (Immunoproliferative Disorders) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 17: Global: Natural Killer Cells Therapeutics (Immunoproliferative Disorders) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 18: Global: Natural Killer Cells Therapeutics (Other Applications) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 19: Global: Natural Killer Cells Therapeutics (Other Applications) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 20: Global: Natural Killer Cells Therapeutics (Hospitals) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 21: Global: Natural Killer Cells Therapeutics (Hospitals) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 22: Global: Natural Killer Cells Therapeutics (Research Centers and Institutes ) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 23: Global: Natural Killer Cells Therapeutics (Research Centers and Institutes ) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 24: Global: Natural Killer Cells Therapeutics (Other End Users) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 25: Global: Natural Killer Cells Therapeutics (Other End Users) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 26: North America: Natural Killer Cells Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 27: North America: Natural Killer Cells Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 28: United States: Natural Killer Cells Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 29: United States: Natural Killer Cells Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 30: Canada: Natural Killer Cells Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 31: Canada: Natural Killer Cells Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 32: Asia-Pacific: Natural Killer Cells Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 33: Asia-Pacific: Natural Killer Cells Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 34: China: Natural Killer Cells Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 35: China: Natural Killer Cells Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 36: Japan: Natural Killer Cells Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 37: Japan: Natural Killer Cells Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 38: India: Natural Killer Cells Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 39: India: Natural Killer Cells Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 40: South Korea: Natural Killer Cells Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 41: South Korea: Natural Killer Cells Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 42: Australia: Natural Killer Cells Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 43: Australia: Natural Killer Cells Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 44: Indonesia: Natural Killer Cells Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 45: Indonesia: Natural Killer Cells Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 46: Others: Natural Killer Cells Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 47: Others: Natural Killer Cells Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 48: Europe: Natural Killer Cells Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 49: Europe: Natural Killer Cells Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 50: Germany: Natural Killer Cells Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 51: Germany: Natural Killer Cells Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 52: France: Natural Killer Cells Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 53: France: Natural Killer Cells Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 54: United Kingdom: Natural Killer Cells Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 55: United Kingdom: Natural Killer Cells Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 56: Italy: Natural Killer Cells Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 57: Italy: Natural Killer Cells Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 58: Spain: Natural Killer Cells Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 59: Spain: Natural Killer Cells Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 60: Russia: Natural Killer Cells Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 61: Russia: Natural Killer Cells Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 62: Others: Natural Killer Cells Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 63: Others: Natural Killer Cells Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 64: Latin America: Natural Killer Cells Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 65: Latin America: Natural Killer Cells Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 66: Brazil: Natural Killer Cells Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 67: Brazil: Natural Killer Cells Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 68: Mexico: Natural Killer Cells Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 69: Mexico: Natural Killer Cells Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 70: Others: Natural Killer Cells Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 71: Others: Natural Killer Cells Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 72: Middle East and Africa: Natural Killer Cells Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 73: Middle East and Africa: Natural Killer Cells Therapeutics Market: Breakup by Country (in %), 2022
  • Figure 74: Middle East and Africa: Natural Killer Cells Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 75: Global: Natural Killer Cells Therapeutics Industry: SWOT Analysis
  • Figure 76: Global: Natural Killer Cells Therapeutics Industry: Value Chain Analysis
  • Figure 77: Global: Natural Killer Cells Therapeutics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Natural Killer Cells Therapeutics Market: Key Industry Highlights, 2022 and 2028
  • Table 2: Global: Natural Killer Cells Therapeutics Market Forecast: Breakup by Therapeutics (in Million US$), 2023-2028
  • Table 3: Global: Natural Killer Cells Therapeutics Market Forecast: Breakup by Application (in Million US$), 2023-2028
  • Table 4: Global: Natural Killer Cells Therapeutics Market Forecast: Breakup by End User (in Million US$), 2023-2028
  • Table 5: Global: Natural Killer Cells Therapeutics Market Forecast: Breakup by Region (in Million US$), 2023-2028
  • Table 6: Global: Natural Killer Cells Therapeutics Market: Competitive Structure
  • Table 7: Global: Natural Killer Cells Therapeutics Market: Key Players
目次
Product Code: SR112023A4214

Abstract

The global natural killer cells therapeutics market size reached US$ 2.5 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 5.4 Billion by 2028, exhibiting a growth rate (CAGR) of 13.70% during 2022-2028.

Natural killer (NK) cells therapeutics target multiple pathogenic antigens with efficient cytotoxicity and reduce the risk of cytokine storms. They can be produced from a variety of sources without relying on patient-specific immune cells. At present, several strategies have been developed, such as ex vivo pre-conditioning with cytokines or small molecular drugs and engineering a chimeric antigen receptor (CAR) NK, which improve the efficacy of NK cells therapeutics. Moreover, researchers are focusing on maximizing the therapeutic effects of allogeneic NK cells through robust expansion, enhanced targeting, and extended persistence of potent immune cells. This can also help unleash a strong and sustained anti-cancer immune-mediated attack.

Natural Killer Cells Therapeutics Market Trends:

A significant rise in the number of individuals with cancer, infectious diseases, and liver disorders represents one of the primary factors fueling the market growth. This can be attributed to unhealthy dietary patterns, lack of physical activities, growing air pollution, and the increasing number of individuals consuming alcohol and tobacco products. Moreover, as the risk of developing cancer rises dramatically with age, the increasing geriatric population across the globe is acting as another growth-inducing factor catalyzing the demand for NK cells therapeutics. Apart from this, as the immune response of cancer patients is not adequate, health companies are developing novel methods and technologies to boost the immune response through allogeneic, off-the-shelf NK cell-based therapies. Furthermore, there is a rise in the number of clinical studies that focus on tumor-targeted antibody strategies to enhance the therapeutic benefit of NK-cell-based therapy while minimizing risks and toxicities. In addition, governing agencies of numerous countries are funding financial schemes for cancer patients, which is creating a favorable outlook for the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global natural killer cells therapeutics market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on therapeutics, application and end user.

Breakup by Therapeutics:

NK Cell Therapies

NK Cell Directed Antibodies

Breakup by Application:

Cancer

Gastrointestinal Diseases

Immunoproliferative Disorders

Others

Breakup by End User:

Hospitals

Research Centers and Institutes

Others

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Affimed GmbH, Bristol-Myers Squibb Company, Fate Therapeutics, Fortress Biotech Inc., Glycostem Therapeutics, Innate Pharma S.A., Kuur Therapeutics Inc. (Athenex Inc.), Nkarta Inc., Takeda Pharmaceutical Company Limited and Ziopharm Oncology Inc.

Key Questions Answered in This Report

  • 1. What was the size of the global natural killer cells therapeutics market in 2022?
  • 2. What is the expected growth rate of the global natural killer cells therapeutics market during 2023-2028?
  • 3. What are the key factors driving the global natural killer cells therapeutics market?
  • 4. What has been the impact of COVID-19 on the global natural killer cells therapeutics market?
  • 5. What is the breakup of the global natural killer cells therapeutics market based on the therapeutics?
  • 6. What is the breakup of the global natural killer cells therapeutics market based on the application?
  • 7. What is the breakup of the global natural killer cells therapeutics market based on the end user?
  • 8. What are the key regions in the global natural killer cells therapeutics market?
  • 9. Who are the key players/companies in the global natural killer cells therapeutics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Natural Killer Cells Therapeutics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Therapeutics

  • 6.1 NK Cell Therapies
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 NK Cell Directed Antibodies
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Application

  • 7.1 Cancer
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Gastrointestinal Diseases
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Immunoproliferative Disorders
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Research Centers and Institutes
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Others
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Affimed GmbH
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
    • 14.3.2 Bristol-Myers Squibb Company
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Fate Therapeutics
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
    • 14.3.4 Fortress Biotech Inc.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
    • 14.3.5 Glycostem Therapeutics
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
    • 14.3.6 Innate Pharma S.A.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
    • 14.3.7 Kuur Therapeutics Inc. (Athenex Inc.)
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
    • 14.3.8 Nkarta Inc.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
    • 14.3.9 Takeda Pharmaceutical Company Limited
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 Ziopharm Oncology Inc.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials